Quick Answer
Resveratrol Cognitive Performance Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Dietary patterns have emerged as modifiable risk factors that may influence disease onset and progression.
Key Takeaways
- 01Dietary patterns have emerged as modifiable risk factors that may influence disease onset and progression. [Fekete M (2025)]
- 02The Mediterranean diet (MedDiet), rich in fruits, vegetables, whole grains, legumes, fish, and extra virgin olive oil, has been consistently associated with better cognitive outcomes and reduced risk of neurodegeneration. [Fekete M (2025)]
- 03Aim: This narrative review summarizes current evidence on the role of the MedDiet in slowing the progression of neurodegenerative diseases, with a particular focus on polyphenols such as resveratrol and oleuropein as key bioactive mediators. [Fekete M (2025)]
- 04Background: Neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, are among the leading causes of disability and mortality worldwide. [Fekete M (2025)]
The current Migaku evidence database contains 1 reusable source document for Resveratrol Cognitive Performance Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Dietary patterns have emerged as modifiable risk factors that may influence disease onset and progression. [Fekete M (2025); evidence level 4]
- The Mediterranean diet (MedDiet), rich in fruits, vegetables, whole grains, legumes, fish, and extra virgin olive oil, has been consistently associated with better cognitive outcomes and reduced risk of neurodegeneration. [Fekete M (2025); evidence level 4]
- Aim: This narrative review summarizes current evidence on the role of the MedDiet in slowing the progression of neurodegenerative diseases, with a particular focus on polyphenols such as resveratrol and oleuropein as key bioactive mediators. [Fekete M (2025); evidence level 4]
- Background: Neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, are among the leading causes of disability and mortality worldwide. [Fekete M (2025); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources